Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders

• Main Authors: Dharmendra Kumar Khatri, Amey Kadbhane, Monica Patel, Shweta Nene, Srividya Atmakuri, Saurabh Srivastava, Shashi Bala Singh
• Format: Article
• Language: English
• Published: Elsevier 2021-01-01
• Series: Current Research in Pharmacology and Drug Discovery
• Subjects: Neurodegenerative diseases; Alzheimer’s disease; Parkinson’s disease; Drug repurposing; Gene therapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S2590257121000092

Neurodegenerative diseases (ND) are of vast origin which are characterized by gradual progressive loss of neurons in the brain region. ND can be classified according to the clinical symptoms present (e.g. Cognitive decline, hyperkinetic, and hypokinetic movements disorder) or by the pathological protein deposited (e.g., Amyloid, tau, Alpha-synuclein, TDP-43). Alzheimer’s disease preceded by Parkinson’s is the most prevalent form of ND world-wide. Multiple factors like aging, genetic mutations, environmental factors, gut microbiota, blood-brain barrier microvascular complication, etc. may increase the predisposition towards ND. Genetic mutation is a major contributor in increasing the susceptibility towards ND, the concept of one disease-one gene is obsolete and now multiple genes are considered to be involved in causing one particular disease. Also, the involvement of multiple pathological mechanisms like oxidative stress, neuroinflammation, mitochondrial dysfunction, etc. contributes to the complexity and makes them difficult to be treated by traditional mono-targeted ligands. In this aspect, the Poly-pharmacological drug approach which targets multiple pathological pathways at the same time provides the best way to treat such complex networked CNS diseases. In this review, we have provided an overview of ND and their pathological origin, along with a brief description of various genes associated with multiple diseases like Alzheimer’s, Parkinson’s, Multiple sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Huntington’s and a comprehensive detail about the Poly-pharmacology approach (MTDLs and Fixed-dose combinations) along with their merits over the traditional single-targeted drug is provided. This review also provides insights into current repurposing strategies along with its regulatory considerations.